This multicenter study evaluated safety and efficacy of adalimumab (ADA) in patients (pts) with moderate to severe hidradenitis suppurativa (HS).
In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa.
The FDA has approved Humira (adalimumab), from AbbVie, for the treatment of moderate to severe hidradenitis suppurativa (HS). It is...
The European Medicines Agency (EMA) has recommended extending the use of Humira (adalimumab) from AbbeVie to include treatment of adults...
Objective: To evaluate the efficacy and safety of adalimumab, an anti-tumor necrosis factor-α antibody, in patients with moderate to severe HS.
AbbVie announced new results from PIONEER II, a pivotal Phase III study, demonstrating the effect of Humira (adalimumab) in reducing...
Introduction: Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha...
AbbVie has announced results from a Phase III pivotal study demonstrating that Humira (adalimumab) is effective in reducing common clinical...
CHMP positive for Awiqli (once-weekly basal insulin icodec) for treatment of diabetes in adults.- Novo Nordisk.
Objectives: To test the efficacy of adalimumab in HS.